Executive Brief

News Report

The News: FDA approves bulevirtide as the first treatment for chronic hepatitis delta virus infection.
Clinical Win: This approval provides a significant advancement in the management of HDV, addressing a critical unmet need.
Target Specialty: gastroenterology

Key Data at a Glance

Approval Date: May 22, 2026
Efficacy Rate: 48% combined response at week 48
Dosing: 8.5 mg once daily
Common Adverse Events: Hypersensitivity reactions, injection site reactions, headache

The FDA approved bulevirtide (Hepcludex) for chronic hepatitis delta virus (HDV) infection, marking the first treatment option available for this serious condition. This approval, announced on May 22, 2026, addresses a critical gap in care for patients who previously had no FDA-approved therapies available for HDV.

Clinical Context

Hepatitis delta virus (HDV) is a unique viral infection that requires the presence of hepatitis B virus (HBV) for its replication. Chronic HDV infection is associated with a more severe disease course, leading to rapid progression towards liver fibrosis, liver cancer, and liver failure. Approximately 5% of individuals with chronic HBV infection are also infected with HDV, which can complicate treatment and worsen patient outcomes. Current management strategies for HBV do not effectively address HDV, creating a significant unmet need in the treatment landscape. The approval of bulevirtide represents a substantial advancement in the management of HDV, offering hope for improved outcomes in affected patients. Bulevirtide acts as an entry inhibitor, blocking the virus's ability to infect liver cells by targeting the sodium taurocholate cotransporting polypeptide (NTCP) receptor, which is essential for HDV entry into hepatocytes.

Key Findings

The FDA approval of bulevirtide (Hepcludex) provides a new treatment option for adults with chronic HDV infection, including those without cirrhosis and those with compensated cirrhosis [5].
The efficacy of bulevirtide was demonstrated in the MYR301 trial, where 48% of patients achieved a combined response at week 48, compared to only 2% in the delayed treatment group [5].
Dosing for bulevirtide is set at 8.5 mg administered once daily, with a treatment duration of up to 144 weeks [5].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Common adverse events reported include hypersensitivity reactions, injection site reactions, headache, abdominal pain, fatigue, and pruritus [5].

What This Means for Clinical Practice

The approval of bulevirtide offers gastroenterologists and hepatologists a critical tool in managing chronic HDV infection, particularly for patients who have not responded to existing HBV therapies. Clinicians should consider bulevirtide for patients meeting the criteria, especially those with advanced liver disease or significant liver inflammation. This new treatment could potentially alter the disease trajectory for many patients, reducing the risk of liver-related complications and improving quality of life. However, ongoing monitoring for adverse effects and the potential for severe acute exacerbations of HDV and HBV upon discontinuation of treatment will be essential in clinical practice. As more data emerges, the integration of bulevirtide into treatment guidelines will be an important consideration for optimizing patient outcomes.

Clinical Perspective

Workflow: The introduction of bulevirtide will require clinicians to assess patients for chronic HDV infection and consider this treatment as part of their management plan.

Economics: With the approval of bulevirtide, healthcare systems may see changes in resource allocation towards the management of HDV, potentially reducing long-term costs associated with liver disease complications.

Patient Outcomes: This treatment could lead to improved patient outcomes by reducing the incidence of severe liver-related complications and enhancing overall quality of life for those affected by chronic HDV.

Dr. Sanjay Iyer, Gastroenterology

FDA Approves Bulevirtide for Chronic Hepatitis Delta Virus: First Treatment Option Available

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Gastroenterology in your inbox.

Related Drug Updates

FDA Approves Bulevirtide for Chronic Hepatitis Delta Virus: First Treatment Available

FDA Approves Bulevirtide for Chronic Hepatitis Delta Virus: New Treatment Algorithm Released

FDA Approves New Biologics Algorithm for Ulcerative Colitis: Golimumab, Vedolizumab, Upadacitinib, and More

Verified HCP Portal